Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 Shares

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 9,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $107.68, for a total value of $969,120.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $842,596. This trade represents a 53.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Trading Up 3.8%

NASDAQ PTGX opened at $109.79 on Friday. Protagonist Therapeutics, Inc. has a 1-year low of $49.38 and a 1-year high of $111.45. The stock has a 50-day moving average of $101.59 and a 200-day moving average of $93.11. The firm has a market cap of $7.06 billion, a PE ratio of -60.66 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The company had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. As a group, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares during the period. Greenline Wealth Management LLC purchased a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $27,000. EverSource Wealth Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the period. Abich Financial Wealth Management LLC purchased a new position in shares of Protagonist Therapeutics during the 3rd quarter worth approximately $62,000. Finally, Hantz Financial Services Inc. grew its holdings in shares of Protagonist Therapeutics by 222.4% during the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after acquiring an additional 656 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Leerink Partners upped their price target on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Wolfe Research assumed coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 price target for the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. upped their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $115.21.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.